BWX Technologies, Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Jim Cramer Weighs In on BWX Technologies After 27% Pullback

Acquisition Divestiture AI-generated analysis

πŸ“‰ BWX Technologies stock has dropped 27% over the past three months following a Q2 report that missed expectations, trading between $130 and $140 after peaking above $241.

πŸ›‘οΈ The company holds a virtual monopoly on manufacturing naval nuclear reactors for U.S. submarines and aircraft carriers, securing a sovereign defense moat.

πŸ“ˆ Total backlog has doubled to $8.4 billion, representing approximately nine quarters of contracted run rate for the core defense business.

πŸ’° BWX Technologies projects 2026 full-year revenue of $3.8 billion, with roughly 98% derived directly from core nuclear activities.

πŸ”„ The company is selling a majority stake in its non-core medical isotope unit for up to $800 million to fund high-return nuclear manufacturing assets.

πŸ—οΈ Proceeds from the sale will support a 500,000-square-foot footprint expansion through the Precision Components Group acquisition.

🎯 Updated 2030 financial targets include annual revenues of $5.5 billion to $6 billion with low double-digit compound organic growth.

πŸ’Ή Adjusted EBITDA margins are expected to expand from 17.5% to approximately 20% by the end of the decade.

πŸ“‰ The stock currently trades at a 36x TTM price-to-earnings multiple, pricing in strong execution of the commercial nuclear supercycle.

⚠️ Structural margin volatility within Government Operations remains a constant reality that limits upside surprises for defense contracting.

πŸ”§ Realizing 20% EBITDA margins depends on scaling unproven commercial SMR production lines and navigating supply chain bottlenecks for specialty alloys.

πŸ“‰ Insider selling has continued, including share sales by CEO Rex Geveden under a Rule 10b5-1 trading plan.

🏦 Hedge fund holders expanded to 65 in the second quarter, with Alkeon Capital Management holding the top position with 2.02 million shares.

πŸ“‰ Short interest remains low at 4.42% of the public float, indicating limited bearish positioning against the stock.

Bullish Signals
  • BWX Technologies holds a virtual monopoly in manufacturing naval nuclear reactors for U.S. submarines and aircraft carriers, providing an irreplaceable sovereign defense moat.
  • Total backlog has doubled to $8.4 billion, representing roughly nine quarters of contracted run rate for the core defense business.
  • The company is selling a majority stake in its non-core medical isotope unit for up to $800 million to reallocate capital into high-return nuclear manufacturing assets.
  • Management targets annual revenues of $5.5 billion to $6 billion by 2030 with low double-digit compound organic growth.
  • Adjusted EBITDA margins are projected to expand from 17.5% to approximately 20% by the end of the decade.
  • Cumulative free cash flow generation is expected to exceed $2 billion through the end of the decade.
  • Hedge fund holders expanded to 65 in the second quarter, with Alkeon Capital Management leading institutional ownership.
  • Jim Cramer views the recent market pullback as a temporary dislocation rather than a structural flaw in the business model.
Risk Factors
  • The stock has endured a severe pullback from 52-week highs of over $241 down into the $130-$140 range, driven by a broader industrial selloff.
  • Structural margin volatility within Government Operations remains a constant reality that frequently limits upside surprises for defense contracting.
  • Realizing projected EBITDA margin expansion depends heavily on scaling unproven commercial SMR production lines while navigating ongoing supply chain bottlenecks for military-grade specialty alloys.
  • Insider selling has continued, including share sales by CEO Rex Geveden under a Rule 10b5-1 trading plan.
  • The market is pricing in strong execution of the commercial nuclear power supercycle at a 36x TTM price-to-earnings multiple, leaving little margin for error.
Full Analysis
Jim Cramer highlighted a significant 27% pullback in BWX Technologies (NYSE:BWXT) stock over the past three months, attributing the decline to a weaker-than-expected Q2 report released on August 3rd. Despite the short-term volatility and broader industrial selloff driving prices down from 52-week highs above $241 to the $130-$140 range, Cramer views the situation as a temporary dislocation rather than a structural flaw in the company's business model. At its September 29 Investor Day, BWX Technologies presented a robust long-term outlook anchored by its monopoly on U.S. Navy naval nuclear reactors for submarines and aircraft carriers. Management reported that total backlog has doubled to $8.4 billion, providing roughly nine quarters of contracted run rate visibility. For the fiscal year 2026, the company projects full-year revenue of $3.8 billion, with approximately 98% generated directly from core nuclear activities. To capitalize on accelerating global demand in defense and commercial nuclear power, BWX Technologies is executing a strategic pivot to focus on high-return assets. The company plans to sell a majority stake in its non-core medical isotope unit for up to $800 million, with proceeds reallocated into manufacturing expansions, including a 500,000-square-foot footprint increase via the Precision Components Group acquisition. This strategy supports updated 2030 targets of annual revenues between $5.5 billion and $6 billion. While the stock trades at a premium valuation of roughly 36x TTM earnings, reflecting high market expectations for commercial nuclear growth, analysts note specific headwinds including structural margin volatility in government operations and supply chain bottlenecks for military-grade alloys. However, hedge fund interest has expanded to 65 holders in Q2, with Alkeon Capital Management leading the pack, suggesting institutional confidence in the company's long-term compounder potential despite near-term valuation compression.